• Carboplatin in Preclinical Oncology: Quantitative Assay Opti

  2026-04-28

  Explore Carboplatin, a platinum-based DNA synthesis inhibitor, through a quantitative lens: this article delivers evidence-backed protocol guidance and practical insights for optimizing cancer research assays—distinct from existing resources by focusing on assay design, reproducibility, and actionable literature synthesis.

• Distinct Apoptotic Pathways in BMECs Induced by Candida krus

  2026-04-28

  Miao et al. (2023) demonstrated that yeast and hypha phases of Candida krusei trigger apoptosis in bovine mammary epithelial cells (BMECs) through separate molecular routes, implicating mitochondrial and death receptor mechanisms. These findings clarify how fungal mastitis develops at a cellular level and highlight the regulatory roles of TLR2/ERK and JNK/ERK signaling, providing a basis for targeted research into bovine mammary gland defense.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-27

  Schwartz’s dissertation critically redefines how in vitro assays capture cancer drug responses, advocating for distinct measurement of proliferative arrest and cell death. These advances support more nuanced interpretation of agents like Axitinib (AG 013736) in angiogenesis inhibition and tumor growth research.

• Lactate-Induced HMGB1 Modification and Exosomal Release in S

  2026-04-27

  This study uncovers how lactate promotes post-translational modifications of HMGB1 in macrophages, facilitating its exosomal release and contributing to the progression of polymicrobial sepsis. The findings reveal novel metabolic-inflammation links and highlight potential intervention points for inflammatory signaling pathway research.

• Carfilzomib (PR-171): Precision Proteasome Inhibition in Mye

  2026-04-26

  Explore how Carfilzomib (PR-171) empowers next-generation proteasome inhibition in multiple myeloma research. This article uniquely connects molecular specificity, emerging biomarker insights, and translational protocol strategies for advanced cancer biology.

• Dimethyloxalylglycine (DMOG): Technical Workflow Guidance

  2026-04-25

  Dimethyloxalylglycine (DMOG) is a cell-permeable inhibitor for controlled hypoxia-inducible factor (HIF) stabilization in mechanistic studies of oxygen sensing, hypoxia signaling, and immune modulation. It is best suited for in vitro and in vivo research workflows where precise, reversible prolyl hydroxylase inhibition is required. DMOG is not intended for diagnostic or therapeutic applications.

• Harnessing SAG to Unlock Hedgehog Signaling in Neurorepair

  2026-04-24

  This thought-leadership piece explores the mechanistic and translational dimensions of Smoothened Agonist (SAG) in Hedgehog pathway research. It connects recent evidence of sex-dependent immune modulation in demyelination with practical guidance for protocol design, while critically examining the competitive landscape and future opportunities for disease modeling and regenerative therapy. This article uniquely bridges mechanistic insight with workflow strategy, providing a roadmap for translational researchers seeking to leverage SAG’s robust and nuanced biology.

• Photothermal-CD47 Blockade Synergy in OSCC: Mechanistic Insi

  2026-04-24

  This article analyzes a recent study demonstrating that photothermal therapy (PTT) enhances the efficacy of CD47 blockade in oral squamous cell carcinoma (OSCC) by inducing calreticulin (CRT) exposure and remodeling the extracellular matrix. These mechanistic advances inform new strategies for combining immuno-oncology and photothermal approaches in solid tumor therapy.

• Advancing In Vitro Drug Response Evaluation in Cancer Resear

  2026-04-23

  Schwartz (2022) critically assessed traditional in vitro methods for evaluating anti-cancer drug responses, revealing that commonly used metrics—relative and fractional viability—capture distinct facets of proliferation arrest and cell death. The study’s nuanced findings underscore the importance of using both measures for a more accurate assessment of drug efficacy, with direct implications for angiogenesis and tumor inhibition assays.

• Carfilzomib (PR-171): Advanced Protocols for Proteasome Inhi

  2026-04-23

  Carfilzomib (PR-171) from APExBIO enables precise, irreversible proteasome inhibition—empowering cancer researchers to dissect apoptosis, cell cycle arrest, and resistance mechanisms with nanomolar potency. This guide delivers actionable workflows, troubleshooting insights, and comparisons to emerging combinatorial regimens for translational oncology.

• PPT (Propyl Pyrazole Triol): Precision in ERα-Driven Researc

  2026-04-22

  This article explores the strategic and mechanistic frontiers enabled by PPT (Propyl Pyrazole Triol), a highly selective ERα agonist. Integrating recent biomarker insights from lung adenocarcinoma studies with practical protocol guidance, it positions PPT as an essential translational tool for dissecting estrogen receptor signaling in oncology and beyond.

• MG-262 (Z-Leu-Leu-Leu-B(OH)2): Precision in Proteasome Inhib

  2026-04-22

  MG-262 (Z-Leu-Leu-Leu-B(OH)2) offers researchers reversible, selective proteasome inhibition, unlocking advanced applications in apoptosis, osteoclast differentiation, and muscle proteostasis studies. This guide distills protocol enhancements, troubleshooting insights, and workflow optimizations for reproducible results across cellular and in vivo systems.

• Protease Inhibitor Cocktail: Elevating Plant Protein Stabili

  2026-04-21

  Unlock reproducible protein preservation in plant research with APExBIO’s EDTA-free Protease Inhibitor Cocktail. Discover workflow enhancements, troubleshooting tips, and the translational impact of robust protein stabilization for advanced plant signaling studies.

• Optimizing Protein Purification with X-press Tag Peptide

  2026-04-21

  The X-press Tag Peptide, an advanced N-terminal leader peptide, streamlines affinity purification and detection in recombinant protein workflows. Its integration of polyhistidine and unique Xpress epitope domains, combined with robust solubility and a precise cleavage site, delivers reproducible, high-yield results for complex mechanistic studies such as neddylation and mTORC1 signaling.

• Dabigatran etexilate in Anticoagulant Research: Protocols &

  2026-04-20

  Dabigatran etexilate is a selective oral direct thrombin inhibitor that streamlines advanced anticoagulant research, offering reproducible, quantitative modulation of coagulation. This article translates clinical insights and experimental benchmarks into actionable workflows, troubleshooting tactics, and protocol enhancements—positioning APExBIO's Dabigatran etexilate as a cornerstone reagent for atrial fibrillation and stroke prevention studies.

16775 records 1/1119 page Next 12345 下5页 Last page